N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE AS A PROGNOSTIC MARKER FOR RESPONSE TO INTENSIVE CHEMOTHERAPY IN ACUTE MYELOID LEUKEMIA PATIENTS
Ghandor, A., Elhadidy, A., Abdelrahman, A., Abdelazim, A., Elgaml, M. (2025). N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE AS A PROGNOSTIC MARKER FOR RESPONSE TO INTENSIVE CHEMOTHERAPY IN ACUTE MYELOID LEUKEMIA PATIENTS. EKB Journal Management System, 7(2), 64-65. doi: 10.21608/alexpo.2025.395499.2193
Ashraf Ghandor; Abeer Shawky Elhadidy; Ahmed Abdelrahman; Ahmed Mokhtar Abdelazim; Mona Mohamed Abd Elaati Elgaml. "N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE AS A PROGNOSTIC MARKER FOR RESPONSE TO INTENSIVE CHEMOTHERAPY IN ACUTE MYELOID LEUKEMIA PATIENTS". EKB Journal Management System, 7, 2, 2025, 64-65. doi: 10.21608/alexpo.2025.395499.2193
Ghandor, A., Elhadidy, A., Abdelrahman, A., Abdelazim, A., Elgaml, M. (2025). 'N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE AS A PROGNOSTIC MARKER FOR RESPONSE TO INTENSIVE CHEMOTHERAPY IN ACUTE MYELOID LEUKEMIA PATIENTS', EKB Journal Management System, 7(2), pp. 64-65. doi: 10.21608/alexpo.2025.395499.2193
Ghandor, A., Elhadidy, A., Abdelrahman, A., Abdelazim, A., Elgaml, M. N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE AS A PROGNOSTIC MARKER FOR RESPONSE TO INTENSIVE CHEMOTHERAPY IN ACUTE MYELOID LEUKEMIA PATIENTS. EKB Journal Management System, 2025; 7(2): 64-65. doi: 10.21608/alexpo.2025.395499.2193

N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE AS A PROGNOSTIC MARKER FOR RESPONSE TO INTENSIVE CHEMOTHERAPY IN ACUTE MYELOID LEUKEMIA PATIENTS

ALEXMED ePosters
Article 1, Volume 7, Issue 2, April 2025, Page 64-65  XML
Document Type: Preliminary preprint short reports of original research
DOI: 10.21608/alexpo.2025.395499.2193
View on SCiNiTO View on SCiNiTO
Authors
Ashraf Ghandor1; Abeer Shawky Elhadidy2; Ahmed Abdelrahman3; Ahmed Mokhtar Abdelazim4; Mona Mohamed Abd Elaati Elgaml email 5
1Department of Internal Medicine, Faculty of Medicine, Alexandria University.
2Department of Clinical and Chemical Pathology, Faculty of Medicine, Alexandria University
3Departments of internal medicine, Hematology, Faculty of Medicine, University of Alexandria, Egypt
4Department of Cardiology, Faculty of Medicine, Alexandria University.
5Department of Internal Medicine, Haematology Unit, Faculty of Medicine, Alexandria University.
Abstract
Acute myeloid leukemia (AML) is a rapidly progressing myeloid neoplasm characterized by the clonal expansion of immature myeloid-derived cells, known as blasts, in the peripheral blood and bone marrow resulting in ineffective erythropoiesis and megakaryopoiesis, clinically manifested as relatively rapid bone marrow failure compared to chronic and indolent leukemias.
Several patient-related factors, including age, poor organ function and especially cardiac comorbidities are prognostic factors in patients with AML. These variables are of particular importance when exploring the ability of patients to tolerate high-dose induction chemotherapy and/or HSCT.
Anthracyclines are cytostatic antibiotics, introduced into the clinical field in the 1960. Unfortunately, anthracyclines are considered the principal culprit drugs behind chemotherapy-induced cardiotoxicity.
A robust laboratory-based biomarker assessing cardiac function and predicting tolerability of chemotherapy and general outcomes is lacking in AML. NT-ProBNP is a biomarker broadly used for the diagnosis, evaluation, and monitoring of cardiomyopathies. In addition, NT-ProBNP is also known to serve as a useful marker for early detection of asymptomatic or imminent heart failure.
Keywords
PRO-BRAIN NATRIURETIC PEPTIDE; AML; Asymptomatic Heart Failure
Supplementary Files
Statistics
Article View: 25